Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07195916 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

A Phase 1 study of Solid Tumors and Hematologic Malignancies, sponsored by Incyte Corporation.

Recruiting
Registry status
Phase 1
Development phase
280
Enrollment target
20
Study locations

NCT07195916 is a Phase 1 study of Solid Tumors and Hematologic Malignancies that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 280 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07195916, a Phase 1 study of Solid Tumors and Hematologic Malignancies, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
Phase 1
Development phase
280 participants
Enrollment target
20
Study locations

Study Summary

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Conditions Studied

Solid Tumors Hematologic Malignancies

Interventions

  • DRUG INCA036873

Study Locations (20)

Other

  • Cliniques Universitaires Ucl Saint-Luc - Brussels
  • Universitair Ziekenhuis Antwerpen - Edegem
  • Universitair Ziekenhuis Gent (Uz Gent) - Ghent
  • Universitair Ziekenhuis Leuven - Leuven
  • Aarhus University Hospital - Aarhus
  • Rigshospitalet Uni of Hospital of Copenhagen - Copenhagen
  • Aou Policlinico S. Orsola-Malpighi - Bologna
  • Fondazione Irccs Istituto Nazionale Dei Tumori - Milan

California

  • City of Hope Medical Center - Duarte
  • University of California San Diego Medical Center, Moores Cancer Center - La Jolla

Tennessee

  • Scri Oncology Partners - Nashville
  • Vanderbilt Medical Center - Nashville

Michigan

  • University of Michigan - Ann Arbor

Nebraska

  • The University of Nebraska Medical Center - Omaha

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • Md Anderson Cancer Center - Houston

New South Wales

  • Macquarie University Hospital - Sydney

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2026-01-08
Est. Completion 2028-08-18
Phase Phase 1

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07195916

The ClinicalTrials.gov registry entry for NCT07195916 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which INCA036873 is the first listed.

NCT07195916 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Tennessee.

Frequently Asked Questions

What is clinical trial NCT07195916 about?

NCT07195916 is a clinical study titled "A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies". A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

What is the current status of trial NCT07195916?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2026-01-08. Estimated completion is 2028-08-18.

What conditions does trial NCT07195916 study?

This clinical trial studies the following conditions: Solid Tumors, Hematologic Malignancies.

What interventions are being tested in trial NCT07195916?

The interventions under investigation include: INCA036873 (DRUG).

Who is sponsoring clinical trial NCT07195916?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07195916 being conducted?

This trial has 20 study locations across California, Michigan, Nebraska, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Hematologic Malignancies

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.